Balloon-Occluded Trans-Arterial Chemo-Embolization Technique with Repeated Alternate Infusion of Cisplatin Solution and Sparse Gelatin Slurry (RAIB-TACE) for Hepatocellular Carcinoma refractory or intolerant to Atezolizumab plus Bevacizumab combination therapy

Hasegawa Naoyuki0 个研究点目标入组 19 人开始时间: 2021年5月26日最近更新: 2024年4月1日

适应症

试验速览

暂无简介。

•1. Patients with hepatocellular carcinoma diagnosed by enhanced CT or MRI
•2. Hepatocellular Carcinoma refractory or intolerant to combination of atezolizumab and bevacizumab
•3. Age: 20 years or older
•4. ECOG Performance Status 0-1
•5. Consent has been obtained from the patient.
•6. The patient is expected to survive for at least 3 months after treatment.

•1. Child pugh score over 8
•2. Renal failure (eGFR <40)
•3. Portal vein or Hepatic vein tumor thrombus
•4. More than 15cm tumor (the maximum tumor size)
•5. Sarcomatous changes (over the course of 2-3 months, the tumor size increases 1.5-2 times or more in size and there is no increase in arterial blood flow. Alternatively, there is a ring of staining with irregular margins and no capsule structure and internal necrosis.
•6. Lymph node involvement or distal metastasis
•7. Previous surgical biliary reconstruction.
•8. Dilation of bile ducts larger than the diameter of the accompanying portal vein at the level of the area or higher.
•9. A severe arterial-portal or arterial-venous shunt is present.
•10. Severe mental impairment.
•11. Severe allergy to iodine contrast medium or cisplatin.
•12. Pregnant or lactating patients.
•13. Other patients who are deemed unsuitable as subjects by the investigator (or subspecialist).
•14. Immune-related Adverse Events that require steroid administratin (more than 30mg/day of prednisolone)

发起方

Hasegawa Naoyuki